We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    evolocumab, 20120356
Previous Study | Return to List | Next Study

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01879319
Recruitment Status : Completed
First Posted : June 17, 2013
Results First Posted : December 23, 2015
Last Update Posted : December 23, 2015
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).

Condition or disease Intervention/treatment Phase
Primary Hypercholesterolemia Mixed Dyslipidemia Biological: Evolocumab AMD Biological: Evolocumab AI/pen Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 164 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.
Study Start Date : July 2013
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Evolocumab

Arm Intervention/treatment
Experimental: Evolocumab AMD
Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
Biological: Evolocumab AMD
Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
Other Names:
  • AMG 145
  • Repatha

Experimental: Evolocumab AI/pen
Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
Biological: Evolocumab AI/pen
Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
Other Names:
  • AMG-145
  • Repatha




Primary Outcome Measures :
  1. Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8 [ Time Frame: Weeks 4 and 8 ]
    Self-administration of evolocumab was assessed by a telephone interview at Weeks 4 and 8. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all. Results only include full administrations that occurred inside the prespecified visit window.


Secondary Outcome Measures :
  1. Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 [ Time Frame: Baseline and Weeks 10 and 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fasting LDL-C at screening > 85 mg/dL
  • Fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L)

Exclusion Criteria:

  • New York Heart Association (NYHA) III or IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
  • Type 1 diabetes or poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01879319


Locations
Layout table for location information
United States, Arizona
Research Site
Phoenix, Arizona, United States, 85020
United States, California
Research Site
Encino, California, United States, 91436
Research Site
Thousand Oaks, California, United States, 91360
Research Site
Tustin, California, United States, 92780
Research Site
Ventura, California, United States, 93003
United States, Florida
Research Site
Port Charlotte, Florida, United States, 33952
Research Site
Saint Augustine, Florida, United States, 32086
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30328
Research Site
Atlanta, Georgia, United States, 30342
Research Site
Gainesville, Georgia, United States, 30501
United States, Kentucky
Research Site
Lexington, Kentucky, United States, 40504
United States, Maine
Research Site
Lewiston, Maine, United States, 04240
United States, Massachusetts
Research Site
Ayer, Massachusetts, United States, 01432
United States, New York
Research Site
Manlius, New York, United States, 13104
United States, Ohio
Research Site
Cadiz, Ohio, United States, 43907
Research Site
Marion, Ohio, United States, 43302
United States, Pennsylvania
Research Site
Duncansville, Pennsylvania, United States, 16635
Research Site
Lansdale, Pennsylvania, United States, 19446
United States, Tennessee
Research Site
Jackson, Tennessee, United States, 38305
Research Site
Nashville, Tennessee, United States, 37203
United States, Texas
Research Site
Austin, Texas, United States, 78731
Research Site
Dallas, Texas, United States, 75231
Canada, British Columbia
Research Site
Burnaby, British Columbia, Canada, V5G 1T4
Canada, Ontario
Research Site
London, Ontario, Canada, N5W 6A2
Research Site
Sarnia, Ontario, Canada, N7T 4X3
Research Site
Toronto, Ontario, Canada, M9V 4B4
Canada, Quebec
Research Site
Pointe-Claire, Quebec, Canada, H9R 3J1
Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01879319    
Other Study ID Numbers: 20120356
First Posted: June 17, 2013    Key Record Dates
Results First Posted: December 23, 2015
Last Update Posted: December 23, 2015
Last Verified: November 2015
Keywords provided by Amgen:
LDL-C, triglycerides, high cholesterol
Additional relevant MeSH terms:
Layout table for MeSH terms
Evolocumab
Hypercholesterolemia
Dyslipidemias
Hyperlipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Antibodies, Monoclonal
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Immunologic Factors
Physiological Effects of Drugs